Tenax Therapeutics, Inc. (TENX) News
Track canonical SquawkNews coverage tagged to TENX, Tenax Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 20 indexed stories across 9 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
TENX plans future trials enrolling sicker patients
TENX says recent trial data missed the primary endpoint but showed strong biological effects, especially in sicker patients, including NT-proBNP and pressure reductions. Future trials will enroll less healthy patients wi
EQUITY | Sep 09, 2026, 02:10 PM UTC
M
TENX conference cites levosimendan biological effects in sicker patients
TradingView News reports a TENX conference highlighted new levosimendan biological effects, especially in sicker patients, despite missing the primary endpoint after enrolling too many healthier subjects. Future trials w
EQUITY | Sep 09, 2026, 01:34 PM UTC
M
TENX reports levosimendan biomarker gains in higher-burden PH-HFpEF
Levosimendan in PH-HFpEF patients with higher baseline disease burden showed significant clinical and biomarker improvements, especially with lower baseline 6MWD, despite not meeting the primary endpoint overall; safety
EQUITY | Sep 09, 2026, 12:13 PM UTC
M
Tenax presents LEVEL topline results; primary endpoint neutral
Tenax reported topline and comprehensive LEVEL results, including about a 49% NT-proBNP reduction and a 3.5 mmHg decline in RVSP, while the trial missed its primary 6MWD endpoint.
REGULATION | Sep 09, 2026, 12:03 PM UTC
L
Tenax Therapeutics CEO to present at 2026 Cantor Healthcare Conference
Tenax Therapeutics said Chris Giordano, President & Chief Executive Officer, will present at the 2026 Cantor Global Healthcare Conference on Wednesday, Sept. 2026.
EQUITY | Sep 01, 2026, 11:07 AM UTC
L
TENX - Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
TENX - Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
EQUITY | Sep 01, 2026, 11:01 AM UTC
H
Top analysts raise targets on Ciena, Deere, Honeywell, NetApp, Tenax
Five Wall Street analysts adjusted ratings or price targets on Ciena, Deere, Honeywell, NetApp and Tenax on Aug. 31.
EARNINGS | Sep 01, 2026, 07:27 AM UTC
H
TENX - Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026 - Click
TENX - Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026
GEOPOLITICS | Aug 29, 2026, 12:27 PM UTC
L
Crude Oil Surges 3%; Sionna Therapeutics Shares Plunge
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 0.2% on Monday. The Dow traded down 0.15% to 53,954.88 while the NASDAQ fell 0.18% to 26,645.53. The S&P 500 also rose, gaining, 0.
EARNINGS | Aug 10, 2026, 04:19 PM UTC
L
US Stocks Edge Lower; Monday.Com Shares Tumble After Q2 Results
U.S. stocks traded mostly lower this morning, with the Dow Jones index falling around 0.2% on Monday. Following the market opening Monday, the Dow traded down 0.16% to 53,949.06 while the NASDAQ fell 0.07% to 26,672.55.
EARNINGS | Aug 10, 2026, 01:40 PM UTC
H
Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Monday. Shares of Airsculpt Technologies Inc (NASDAQ: AIRS ) fell sharply in pre-market trading following second-quarter results. Ai
EARNINGS | Aug 10, 2026, 12:02 PM UTC
L
TENX Tenax Therapeutics RESULTS: Q2, Q2 operating expenses $18.784M, Q2 Operating Income $-18.784M, Q2 Net Income $-17.803M
TENX Tenax Therapeutics RESULTS: Q2, Q2 operating expenses $18.784M, Q2 Operating Income $-18.784M, Q2 Net Income $-17.803M
EARNINGS | Jul 31, 2026, 11:01 AM UTC
L
TENX - Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
TENX - Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
EARNINGS | Jul 31, 2026, 11:00 AM UTC
L
TENX Initiated at Buy and $35 PT @ Canaccord
TENX Initiated at Buy and $35 PT @ Canaccord
EQUITY | Jul 28, 2026, 01:17 PM UTC
L
TENX new Outperform W/ $39 PT @ Evercore
TENX new Outperform W/ $39 PT @ Evercore
EQUITY | Jul 22, 2026, 12:48 PM UTC
H
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Liminatus Pharma (NASDAQ: LIMN ) stock increased by 40.9% to $0.16 during Thursday's pre-market session. The market value of their outstanding shares is at $5.8 million. Stablecoin Development (AMEX: SDEV ) stock
EARNINGS | Jul 02, 2026, 12:05 PM UTC
H
Tenax Therapeutics shares are trading higher after the company announced that it will present results from the Phase 3 LEVEL clinical trial
Tenax Therapeutics shares are trading higher after the company announced that it will present results from the Phase 3 LEVEL clinical trial in a Late-Breaking Clinical Science session at the European Society of Cardiolog
GEOPOLITICS | Jul 02, 2026, 11:46 AM UTC
H
Tenax Therapeutics To Present Results From Phase 3 LEVEL Clinical Trial In Late-Breaking Clinical Science Session At ESC Congress 2026
Abstract recently submitted in anticipation of initial data analysis ahead of ESC Company expects to report topline LEVEL results in August CHAPEL HILL, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (N
GEOPOLITICS | Jul 02, 2026, 11:03 AM UTC
M
TENX: Guggenheim Raises PT
Guggenheim maintains buy rating on Tenax Therapeutics and raises price target to $40
EQUITY | Jun 22, 2026, 01:40 PM UTC
M
TENX: Chardan Initiates Buy
Chardan Capital initiates coverage on Tenax Therapeutics with a buy rating and a price target of $27
EQUITY | Jun 22, 2026, 12:50 PM UTC